Prescription of and Adherence to Non-Steroidal Anti-Inflammatory Drugs and Gastroprotective Agents in At-Risk Gastrointestinal Patients
Authors:
- Angel LanasALAngel Lanas
- Mónica Polo-TomásMPMónica Polo-Tomás
- Pilar RoncalesPRPilar Roncales
- Miguel A GonzalezMGMiguel A Gonzalez
- Javier ZapardielJZJavier Zapardiel
Open Access
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 107 (5) , 707-714
Abstract
Ve, multicenter, observational, longitudinal study. Patients attending rheumatology/orthopedic clinics who were co-prescribed NSAID plus GPA for at least 15 days and had risk factors for GI complications were followed up by telephone call. Optimal adherence was defined as taking the drug for ≥80% of prescribed days. Multivariate logistic regression analysis was used to determine factors associated with non-adherence. RESULTS: Of 1,232 patients interviewed, 192 were excluded because of inaccurate data. Of the remaining 1,040 patients, 74% were prescribed low-dose NSAIDs and 99.8% were prescribed a standard or high-dose GPA. In all, 70% of NSAIDs and 63.1% of GPA prescriptions were short term (<30 days). The majority of patients who were prescribed either an NSAID (92.5%) or GPA (85.9%) started therapy. Optimal adherence to GPA or NSAIDs was reported by 79.7% (95% confidence interval (CI): 76.9−82.2%) and 84.1% (95% CI: 81.7−86.3%) of patients, respectively. More adverse events occurred among patients who reported non-optimal adherence than among patients with optimal adherence to GPA (22.1 vs. 1.9%,P<0.0001). As reasons for non-adherence, patients most frequently cited infrequent/low-intensity rheumatic pain (NSAIDs) or forgetfulness (GPAs). Adverse events and short-term treatment were independent factors associated with poor adherence for both NSAIDs and GPAs. History of uncomplicated peptic ulcer and frequent dosing were additional factors associated with non-adherence to NSAIDs. CONCLUSIONS: Most frequent reasons for non-adherence are infrequent/low-intensity rheumatic pain (NSAIDs) or forgetfulness (GPAs). Short-term treatment and adverse events were associated with poor adherence for both therapies....Keywords
This publication has 23 references indexed in Scilit:
- Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugsDigestive and Liver Disease, 2011
- Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA studyAnnals of the Rheumatic Diseases, 2010
- Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trialThe Lancet, 2010
- Time‐trends in gastroprotection with nonsteroidal anti‐inflammatory drugs (NSAIDs)Alimentary Pharmacology & Therapeutics, 2010
- One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Preference and Adherence, 2010
- Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonThe Lancet, 2007
- National Adherence to Evidence-Based Guidelines for the Prescription of Nonsteroidal Anti-Inflammatory DrugsGastroenterology, 2005
- Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugsAlimentary Pharmacology & Therapeutics, 2003
- Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacinPharmacoepidemiology and Drug Safety, 2000
- Epidemiology of NSAID induced gastrointestinal complications.1999